A major challenge in cancer research is to determine the biological and clinical significance of somatic mutations in non-coding regions. This has been studied in terms of recurrence, functional impact, and association to individual regulatory sites, but the combinatorial contribution of mutations at common RNA regulatory motifs has not been explored. We developed a new method, MIRA, to perform the first comprehensive study of significantly mutated regions (SMRs) with overrepresented binding sites for RNA-binding proteins (RBPs) in cancer. We found multiple RBP motifs, including SRSF10, PCBP1 and HNRPLL motifs, as well as a specific subset of 5' and 3' splice-site sequences, enriched in cancer mutations. Gene targets showed association to cancer-related functions, and analysis of RNA sequencing from the same samples identified alterations in RNA processing linked to these mutations. MIRA facilitates the integrative analysis of multiple genome sites that operate collectively through common RBPs and can aid in the interpretation of non-coding variants in cancer. MIRA is available at https://github.com/comprna/mira.
Introduction
Cancer arises from genetic and epigenetic alterations that interfere with essential mechanisms of the normal life cycle of cells such as DNA repair, replication control, and cell death (Hanahan and Weinberg 2011) . The search for cancer driver mutations, which confer a selective advantage to cancer cells, has been traditionally performed in terms of how they directly affect protein sequences (Vogelstein et al. 2013) . However, systematic studies of cancer genomes have highlighted relevant mutational processes outside of protein-coding regions (Alexandrov et al. 2013b; Weinhold et al. 2014; Juul et al. 2017) and tumorigenic mutations at non-coding regions have been described, like those found in the TERT promoter (Horn et al. 2013; Huang et al. 2013 ). However, a major challenge remains to more accurately and comprehensively determine the significance and potential pathogenic involvement of somatic variants in regions that do not code for proteins (Piraino and Furney 2016) . Current methods to detect potential driver mutations in non-coding regions have been generally based on 1) the recurrence of mutations in predefined regions in combination with measurement of potential functional impacts (Melton et al. 2015; Fredriksson et al. 2014; Mularoni et al. 2016; Weinhold et al. 2014) , 2) recurrence in combination with sequence conservation or polymorphism data (Khurana et al. 2016; Piraino and Furney 2017) , or 3) the enrichment of mutations with respect to specific mutational backgrounds (Lochovsky et al. 2015; Lanzós et al. 2017; Juul et al. 2017);  and some of them have combined multiple such approaches (Juul et al. 2017) . However, these methods have so far been restricted to individual genomic positions rather than combining the contributions from multiple functionally equivalent regulatory sites and additionally, have not evaluated the impact on RNA processing measured from the same patient samples.
Mutations on RNA regulatory sequences can impact RNA processing and lead to disease (Soemedi et al. 2017) . Studies carried out so far on mutations affecting RNA processing and alternative splicing have mainly focused on a fraction of the motifs associated with the core splicing machinery (Jung et al. 2015) , or to protein-coding regions (Supek et al. 2014; Anczuków et al. 2015) . Mutations at exon-intron boundaries have been associated with intron retention in tumor suppressors (Jung et al. 2015) , whereas mutations on coding exons can trigger oncogenic splicing changes (Supek et al. 2014; Anczuków et al. 2015) . In vitro screenings of sequence variants in exons has revealed that more than 50% of nucleotide substitutions can induce splicing changes (Ke et al. 2011; Julien et al. 2016) , with similar effects for synonymous and non-synonymous sites (Julien et al. 2016) . Since RBP binding motifs are widespread along gene loci, and somatic mutations may occur anywhere along the genome, it is possible that mutations in other genic regions could impact RNA processing and contribute to the tumor phenotype. Although mutations and expression alterations in genes coding for RNA binding proteins (RBPs) have an impact on specific cellular programs in cancer, it is not known yet if mutations in the binding sites of RBPs are frequent in cancer, could be damaging to RNA processing, and contribute to oncogenic mechanisms.
To understand the effects of somatic mutations on RNA processing in cancer at a global level we have developed a new approach called MIRA to carry out a comprehensive study of somatic mutation patterns in exons and introns from coding and non-coding genes that operate collectively through interacting with common RBPs. Compared with other existing approaches to detect relevant mutations in non-coding regions, our study provides several novelties and advantages: 1) we searched exhaustively along gene loci, hence increasing the potential to uncover deep intronic pathological mutations; 2) we studied the enrichment of a large compendium of potential RNA regulatory motifs, allowing us to identify potentially novel mechanisms affecting RNA processing in cancer; 3) we showed that multiple mutated genomic loci potentially interact with common RBPs, suggesting novel cancer-related mechanisms; and 4) unlike previous methods, we used RNA sequencing data from the same samples to measure the impact on RNA processing. Our study uncovered multiple sites common to RBPs that impact RNA processing of functions with potential implications in cancer. This study reveals a new layer of insight to aid in the functional interpretation of somatic alterations in cancer, and could also help in interpreting the clinical relevance of non-coding variants in cancer genomes.
Results

Unbiased search for significantly mutated regions (SMRs) along gene loci
RNA binding proteins (RBPs) generally interact with pre-mRNAs at motifs of 4-7 nucleotides, which occur anywhere along the pre-mRNA. We thus performed an exhaustive detection of mutation enrichment along overlapping genomic windows of 7 nucleotides (7-mers) along each gene locus (Fig. 1a) (Methods) . Using a dataset of somatic mutations from whole-genome sequencing (WGS) from 505 samples for 14 tumor types (Fredriksson et al. 2014 ) (PAN505) (Table S1 ), we performed a double statistical test. First, to account for local variations in mutational processes, we tested each 7-mer window for enrichment in number of mutations by comparing each window against the mutation rate for the entire gene locus, and we selected an enrichment p-value threshold of < 0.05 after correcting for multiple tests ( Figure S1a )(Methods).
Secondly, to account for nucleotide biases, we compared the mutation count in each 7-mer window with the expected mutation count calculated from the nucleotide sequence of the window and the mutation rate per nucleotide at the same gene locus. With this we defined a nucleotide bias (NB) score per window as the log2-likelihood of the observed versus the expected counts (Methods). Of the 140,704 windows with 3 or more mutations, 93,497 (66%) showed NB-score > 6, whereas of the 45,916,437 7-mer windows with 1 mutation, which we considered to reflect the mutational background, 1,557,310 (3%) had NB-score > 6 (Chi-square test p-value < 2.2e-16) (Additional file 2: Figure S1b ). We thus selected NB-score > 6 as a cutoff. After applying these filters (corrected p-value < 0.05 and NB score > 6), our exhaustive analysis produced a total of 78,352 significant 7-mer windows in 8,159 genes.
The functional impact of somatic mutations depends on the specific genic region in which they fall. We thus separated the 7-mer windows according to whether they were in a 5' or 3' untranslated region (5UTR/3UTR), a coding sequence (CDS), an exon in a long non-coding RNA (EXON), an intron (INTRON), or in a 5' or 3' splice site (5SS/3SS) (Fig. 1a) (Methods).
These windows were then clustered into significantly mutated regions (SMRs), producing a total of 20,307 SMRs, containing a total of 41,756 substitutions ( Figure S1c ) (Tables S2 and S3), which we considered for further analysis. Most of the predicted SMRs were 7-15 nucleotides long ( Figure S2 ), and the majority of SMRs were in introns or in exons of non-coding RNAs (EXON) ( Table 1) . Total  With  enriched  motifs   With labeled  enriched  motifs   Impact on  RNAprocessing  3SS  823  341  335  2  3UTR  294  44  44  7  5SS  1054  546  521  11  5UTR  119  45  45  5  CDS  208  10  10  3  EXON  335  119  114  12  INTRON  17474  3176 1812 427 with stranded enriched motifs that we could label (with labeled enriched motifs), and with a significant association to an RNA-processing change (impact on RNA-processing). In this latter case we count changes in exon-exon junctions and transcript expression changes.
SMRs
Validation of predicted SMRs
To test our predicted SMRs for possible biases we calculated in each region the DNA replication timing, which is known to correlate with somatic mutations in cancers and can be a source of artefacts in mutational driver predictions (Lawrence et al. 2013; Liu et al. 2013) ; we observed no association with mutation count ( Figure S3 ). Another potential source of artefacts is the relation between gene expression and the rate of somatic mutations (Lawrence et al. 2013) . We used RNA sequencing (RNA-seq) data from the same samples to measure the expression of transcripts whose genomic sequence contained significant regions and observed no association between the mutation count and expression ( Figure S4 ). To further validate our SMRs we used LARVA (Lochovsky et al. 2015) to assess their significance using a statistical model that accounts for over-dispersion of the mutation rate and replication timing (Methods). We observed an overall high similarity between the significance provided by our method and that given by LARVA ( Figure S5 ). In particular, we found a strong agreement for INTRON SMRs (Pearson's R = 0.83), providing support for our intronic predicted regions.
Predicted SMRs recovered known and novel mutational hotspots
We found SMRs in 501 cancer-driver genes out of 889 collected from the literature (Sebestyén et al. 2016) (Fig. 1b) (Figure S7 ), which is more than expected by chance (Fisher's exact test pvalue = 2.2e-16, odds-ratio = 4.6, comparing cancer/non-cancer genes tested with/without SMRs). In particular, we recovered SMRs in 71 genes out of the 108 previously identified with a method that measured the functional impact of mutations (Mularoni et al. 2016) . In agreement with prior findings (Mularoni et al. 2016) , we observed CDS SMRs in a total of 34 cancer genes, including BRAF, IDH1, KRAS, PIK3CA and PIK3R1 (Fig. 1b) . We also found SMRs in SF3B1, CTNNB1, TP53 and KRAS, which were recovered before with a method based on mutation enrichment and evolutionary conservation (Piraino and Furney 2017) . We also found CDS SMRs in cancer genes not found previously, including NRAS, EP300 and ATM (Fig. 1c) . From the 133 genes with predicted 5UTR SMRs, 17 were identified previously (Mularoni et al. 2016 );
and we found 5UTR SMRs in 8 cancer genes, including SPOP and EEF1A1. We found 3UTR
SMRs in 3 of the 12 different genes identified before (Mularoni et al. 2016) , and found 3UTR (Fig. 1c) . Finally, we found 62 5SS SMRs and 53 3SS SMRs in cancer genes, including MET, CHEK2, BRCA1, VEGFA, RB1, CDKN2A, as well as TP53, PTEN and CHD1, which were described before to have mutations at splice-sites (Jung et al. 2015) . In summary, our SMRs provide a rich resource with potential to understand non-coding alterations in cancer.
Somatic mutations show positional biases on RBP binding motifs
To further understand the properties of our SMRs we calculated the mutation frequencies at trinucleotides considering the strand of the gene in which the SMR was defined. We observed an enrichment of C>T and G>A mutations on SMRs (Fig. 2a, upper panel) . However, the stranded triplets showed mutation frequencies similar to their reverse complements, indicating that a considerable proportion of SMRs reflected DNA-related selection processes.
To identify those SMRs that more clearly reflect RNA-related selection processes we studied sequence motifs potentially related to RNA processing regulation. We performed an unbiased k-mer enrichment analysis in SMRs, using k=6. For each SMR type, we compared the proportion of SMRs in which each 6-mer occurs with the proportion in 100 control region sets (Methods). Further, to keep only those potentially associated with RNA rather than DNA, we reverse-complemented all SMRs and control sequences and repeated the enrichment analysis.
Those 6-mers enriched in both calculations for the same region-type were eliminated ( Figure   S7 ). We found a total of 357 enriched 6-mers (Table S4) in 3546 SMRs from all region types (Table S4 ). Enriched 6-mers were AC-rich in CDS regions, GC-rich in 5UTR regions, and T-rich in 3UTR and EXON regions, whereas in 5SS and 3SS regions they were G and A rich, respectively ( Figure S7 ). In contrast, INTRON motifs showed a uniform nucleotide content ( Figure S7 ). Enriched 6-mers showed a different mutational pattern compared to that for all SMRs ( Fig. 2a ) (Tables S5 and S6 ). The symmetry between stranded triplets and their reverse complements in SMRs was no longer present in enriched 6-mers, and there was an enrichment of mutations at AGA and TCC triples that is not recapitulated in their reverse complements, indicating that the selected enriched 6-mers reflect RNA-related selection processes.
From the 74 enriched 6-mers found on 5SS SMRs, 46 contained the 5' splice-site (5ss) consensus GT. These enriched 5'ss motifs showed the consensus G|GT(A/G)AG with a strong conservation of G at the +5 intronic position (position 7 in Fig. 2b ). The highest density of mutations occurred at two positions on either side of the exon-intron boundary (Fig. 2b) , with mostly G>A and G>T substitutions (Fig. 2c) . From the 52 enriched 6-mers found on 3SS SMRs, 36 contained the 3' splice site (3'ss) consensus AG, which showed a strong CNCAG|(G/A) motif, with strong conservation of C nucleotides at the -5 position of the intron (position 1 in Fig.   2c ) and with positions -1 and -3 (3 and 5 in Fig. 2c ) being the most frequently mutated positions, with the most frequent substitution C>T at position -3, and G>A or G>T at position -1 (Fig. 2c ).
Among the cases found, there was a 5'ss in NF1 with mutations in skin (SKCM), lung (LUAD) and uterine (UCEC) tumors (Fig. 2d) , and a 3'ss in FGFR3 with mutations in head and neck (HNSC) and bladder (BLCA) tumors (Fig. 2e ). Mutations at splice site motifs occurred in higher proportions in lung tumors (LUAD, LUSC) and in uterine tumors (UCEC), 5'ss mutations appeared also more frequent in bladder tumors (BLCA), whereas at 3'ss motifs were more frequent in colorectal tumors (CRC) (Fig. 3a) .
To identify RBPs that could potentially bind the enriched 6-mers beyond 5'/3'ss motifs, we used DeepBind (Alipanahi et al. 2015) to score the 6-mers using models for 522 proteins containing KH, RRM and C2H2 domains from human, mouse and Drosophila ( Figure S7 ) (Methods). Using this procedure we labeled 245 (68.6% of the 357 enriched 6-mers; Table S3 ).
In 5SS and 3SS SMRs, besides the enriched 5'ss or 3'ss consensus motifs, we identified binding sites for multiple RBPs (Figs. 3a and 3b) , including motifs for SRSF10, a splicing factor that regulates an alternative splicing response to DNA damage (Chabot and Shkreta 2016) .
SRSF10 motifs appeared also at CDS and INTRON SMRs (Figs. 3c and 3d) ( Figure S8 ). The observed differences in the consensus motif between region types may reflect differences in binding affinities and nucleotide composition, which have been observed before for other RBPs (Lovci et al. 2013) . In 3SS SMRs we also found binding sites for HNRPLL (Fig. 3b ), a regulator of T cell activation through alternative splicing (Oberdoerffer et al. 2008) , which was also found on EXON and INTRON SMRs ( To evaluate the mutational patterns on these motifs, we studied whether particular positions in the enriched motifs were more frequently mutated than others. For each RBP, we thus grouped the SMRs containing the enriched labelled 6-mers and performed a multiple At 5UTR SMRs we found multiple T-and C-rich motifs, which occurred predominantly in melanoma (SKCM) ( Fig. 4a ) (Table S3 ). In particular, PCBP3 and PTBP1 motifs at 5UTR SMRs were characterized by an enrichment of C>T substitutions ( Fig. 4b ) ( Figure S10 ). These motifs might be related to the so-called 5' terminal oligo-pyrimidine tract (5'TOP) motif that is relevant for translational regulation and is bound by multiple RBPs (Sawicka et al. 2008; Pichon et al. 2012 ); these mutations found could indicate cancer-related alterations of translation. At 5UTR
SMRs there were also G-rich motifs (HNRPLL, HNRNPA2B1) with frequent G>A mutations ( Figure S10 ). At 3UTR SMRs, the representation of enriched motifs across tumor types was more variable (Fig. 4c ). There were also CT-rich motifs, including PTBP1, HNRNPC, PCBP3, IGF2BP2 and ELAVL1 (HuR) ( Figure S11 ), but these were more frequent in CRC, BLCA and UCEC patients (Fig. 4c ). For HNRNPC and other RBPs, although C>T appeared as the most recurrent mutation, there were also frequent T>C and T>G mutations ( Fig. 4d ) ( Figure S11 ). We also found the ACA-containing IGF2BP2 motif, which was more prominent in UCEC and CRC, and showed enrichment of C>T mutations ( Figure S11 ).
For each enriched motif, we calculated the enrichment of gene sets (GO Biological Function, Pathways and Oncogenic Pathways) in the genes harboring SMRs with the motif (Table S7 ) (Methods). We found only a few motifs associated with cancer-related functions.
Genes harboring SMRs with 5'ss motifs (5SSC) show enrichment in apoptosis and DNA damage response functions, as well as in genes related to NFKB activation and PI3K signal cascade ( Figure S12 ). Genes with SMRs harboring SRSF10 motifs show association to apoptosis and immune response, whereas genes with HNRNPC or HNRNPLL motifs in SMRs are related to metabolic processes ( Figure S12 ). RBM41-motif containing SMRs are also related to genes involved in metabolic processes, as well as in T-cell activation ( Figure S12 ). These results indicate that cancer mutations on RBP motifs may impact to a wide range of functions besides contributing to oncogenic processes.
Somatic mutations in RBP binding motifs impact in RNA expression and splicing
To determine the impact of the described mutations in enriched motifs we decided to test their impact on RNA processing. We first estimated the association of mutations with changes in transcript isoform expression. For each patient with a mutated SMR we considered each transcript overlapping the SMR and compared its abundance with the distribution of abundances of the same transcript in patients from the same tumor type that did not harbor any mutation in the same SMR. From the 20,308 SMRs tested, 148 showed an association with a significant expression change ( Fig. 5a ) (Table S8) (Magnani et al. 2011 ).
In the case of PBX1, two transcript isoforms change expression in opposite directions, indicating an isoform switch ( Figure S14 ).
We also found mutations in an intronic SRSF10 motif associated with expression changes in a transcript from the dystrophin gene (DMD) in breast cancer (BRCA), and in two transcripts from the Mitogen-Activated Protein Kinase 10 MAPK10 (JNK3) in colorectal cancer (CRC) (Fig. 5c ). In DMD, the mutation was associated with increased expression, whereas in MAPK10 we observed an isoform switch (Fig. 5c ). MAPK10 is a pro-apoptotic gene, whose alternative splicing has been observed in colon tumors (Ying et al. 2006; Sebestyén et al. 2016) Our results suggest that a mutation in an intronic SRSF10 motif conserved in primates is responsible for this splicing change in CRC (Fig. 5c) . We also found a CRC mutation on an intronic MBNL1 motif conserved in mammals that is associated with an upregulation of the transcription factor ETV1 (Fig. 5d) , which has been linked to prostate cancer (Cai et al. 2007) . A mutation at a nearby site in SKCM appears to induce downregulation of a different transcript isoform (Fig. 5d) .
In 5UTR SMRs, significant changes were associated only with SKCM mutations ( Figure   S15 ). One of these changes corresponds to a mutation on a PCBP3 motif associated with an isoform switch in the galactokinase-2 gene GALK2 in melanomas ( Figure S15 ). GALK2 was found to be a regulator of prostate cancer cell growth (Whitworth et al. 2012 ) and showed extensive, alternative first-exon splicing in multiple tumor types (Sebestyén et al. 2016 ). Here we showed that these splicing alterations could stem from a mutation at the 5'UTR. Finally, among the changes associated with 3UTR SMRs, we found a mutation in a HuR (ELAVL1) motif in CRC related to the downregulation of the Debrin-like gene DBNL ( Figure S15 ).
We also analyzed all possible exon-exon junctions defined from spliced reads mapped to the genome, and for each patient we compared the relative junction inclusion level overlapping a given SMR with the distribution of inclusion levels of the same junction in patients from the same tumor type but without mutations in the same SMR (Methods). Of the SMRs tested, 30 were associated with a significant inclusion change in at least one junction ( Fig. 6a) ( Table S9 ). The majority of cases were associated with INTRON SMRs, were more abundant in bladder tumors (BLCA) and head and neck squamous-cell tumors (HNSC). Significant junctions were also commonly associated with 5SS SMRs, mainly in uterine (UCEC) and skin (SKCM) cancers (Fig. 6a) . Additionally, there were many significant associations in 5UTRs SMRs, specifically for SKCM. In contrast, we found fewer associations for 3SS SMRs, and no association for CDS SMRs (Fig. 6a ).
Significant changes in exon-exon junctions were most commonly associated to the 5' and 3' splice site consensus sequences (5SSC and 3SSC in Fig. 6b ) and to IGF2BP2, HNRNPA2B1, HNRNPLL and PCBP1 motifs among others (Fig. 6b) . Among the significant changes associated to 5SS SMRs (Fig. 6c) , the peptidyl-tRNA hydrolase 2 gene PTRH2 was associated with a mutation in uterine cancer (UCEC), which would lead to the recognition of an upstream cryptic 5'ss (Fig. 6d) . PTRH2 induces anoikis; its downregulation is linked to metastasis in tumor cells (Karmali et al. 2011) and was proposed as a prognostic marker in ovarian cancer (Hua et al. 2013 ). The mutation observed in uterine cancer could therefore play a role in cancer progression. We also found a significant splicing change in the Farnesyl Pyrophosphate Synthetase gene FDPS in melanoma that would produce an alternative 5'ss and skip part of the Polyprenyl synthetase domain ( Figure S16 ). FDPS induces autophagy in cancer cells (Wasko et al. 2011) , and an alteration of the autophagy pathway has been related to myeloid neoplasms when SF3B1 mutations are present (Visconte et al. 2017) . It would be interesting to investigate further whether this splicing-induced alteration of FDPS could recapitulate a similar phenotype. Among the significant changes associated with 3SS mutations ( Figure S16 ) there was one in the Adenine Phosphoribosyl transferase gene APRT associated to G>A mutations at the consensus 3'ss splice site in melanoma (SKCM), which would skip the Phosphoribosyl transferase domain ( Figure S16 ).
We also found mutations in 5UTR motifs associated to splicing changes (Fig. 6e ).
Among the significant cases, we found one in C16orf59 associated with mutations in a HNRPLL motif conserved across mammals (Fig. 6f) . On the other hand, among the splicing changes associated to EXON mutations, we found one in the C14orf37 locus associated to LUAD mutations in an IGF2BP2 in an exon of a non-coding transcript ( Figure S16 ). Finally, INTRON SMRs had the most numerous number of junction changes with mutations in multiple RBP motifs, including RBM8A and SRSF10 ( Figure S17 ). We found a significant change in two junctions in the histone gene HIST1H2AC related to mutations in the RBM8A motif in HNSC, and in GMEB1 related to mutations in an SRSF10 motif ( Figure S17 ). BED and GFF tracks representing all the found cases are available as supplementary material (Table S10 ).
Discussion
We have described a novel method to identify and characterize somatic mutations in coding and non-coding regions in relation to their potential to be involved in common protein-RNA binding.
By considering mutational significance in combination with the enrichment of RBP binding motifs, we identified mutations in non-coding regions, and especially in deep intronic regions, with evidence of an impact on RNA processing. Our analysis provides evidence for new potential mechanisms by which somatic mutations impact RNA processing and contribute to tumor phenotypes. RBPs are known to control entire cellular pathways, from epithelial-tomesenchymal transition (Shapiro et al. 2011 ) to cellular differentiation (Han et al. 2013 ). This suggests a general model in which some of the mutations occurring in cancer anywhere along genes could disrupt the function of targets of a given RBP and contribute independently to the disruption of similar pathways (Fig. 7 ). This provides a new strategy to interpret non-coding mutations and, moreover, indicates that lowly recurrent mutations could still be relevant to the study of cancer, as they can contribute to tumor phenotypes by impacting functions collectively controlled by the same RBP.
Our methodology presents several advantages with respect to previous methods. We can detect deep intronic mutations, whereas other methods have only tested positions on exons or in intronic regions immediately adjacent to exons (Lanzós et al. 2017; Mularoni et al. 2016 ).
Additionally, unlike previous methods (Mularoni et al. 2016; Piraino and Furney 2017; Lanzós et al. 2017) , we examined the location of the mutations in the context of regulatory motifs, which was essential to enable the interpretation of the non-coding mutations and to identify regulatory mechanisms that may be altered in cancer. Previous methods attempting to describe recurrent mutations in splice-sites have tested either just a small window around exon-intron boundaries (Jung et al. 2015) or a region too large and undefined to provide substantial mechanistic insight (Mularoni et al. 2016 ). In our method, the definition of SMRs and motif enrichment is driven by the positions of the mutations, hence providing the precise regions where the mutations are likely to play a role. Furthermore, we did not assume any specific functional impact, like secondary structure or conservation, as not all non-coding regions function through a structure or are necessarily conserved. Other features may determine the processing, stability and function of pre-mRNA or mature RNA molecules, and here we assumed that these are mediated through their ability to interact with proteins. Finally, unlike most previous approaches, we tested the impact on RNA processing and expression using RNA-seq from the same samples. We observed significant changes for a small fraction of SMRs, indicating that the overall impact on RNA is modest. We found multiple intronic SMRs associated to an impacted in RNA processing, which represent new genetic alterations with potential relevance to cancer. Some of these intronic SMRs occurred in non-coding RNAs. Other methods assumed that the function of lncRNAs may be impacted only through exonic mutations (Lanzós et al. 2017) . We also found 5UTR SMRs associated to RNA processing changes. Although it has been assumed that RNA structure determines the function in UTR regions (Mularoni et al. 2016) , our results suggest alternative mechanisms.
Our approach is subject to several limitations. The analysis may be underpowered due to the relatively small number of patients analyzed. For instance, applying our approach to another data set (Alexandrov et al. 2013a ) with 507 patients, we detected no enriched RBPs and limited overlap of the SMRs with the ones described here (data not shown). This indicates that many more samples will be required to detect all possible mutations impacting RNA processing. Another limitation is that to be able to identify functionally analogous regions, we had to choose specific descriptions for the RNA binding motifs. The analysis is thus limited by how accurate these descriptions were. Short nucleotide strings hold sufficient information to describe protein-RNA interactions (Daubner et al. 2013 ). However, despite computational and technological advances, precise definitions of RBP binding sites at a genome scale remains challenging. Additionally, different RBPs bind very similar sequence motifs; hence the identification of some protein-RNA interactions may be ambiguous. Accordingly, we expect that some of the RBP label assignments could be improved. For instance, the described CT-rich motifs at 5'UTRs and AG-rich motifs in introns could correspond to multiple RBPs.
In summary, our data provides evidence that multiple RNA processing mechanisms may be impaired through cancer mutations. Although non-coding mutations with an impact on RNA only occur in few patients, our results motivate the extension of current methods to analyze noncoding mutations to account for functional analogous sites at different genomic positions, which will allow describing similar phenotypes arising from different alterations.
Methods
Detection of significantly mutated regions
We aimed to identify significantly mutated regions (SMRs) in both coding and non-coding regions of genes, taking into account regional and sequence mutational biases. We used the Gencode gene annotations (v19), excluding pseudogenes. To define gene loci unequivocally, we clustered transcripts that shared a splice site on the same strand, and considered the gene to be the genomic locus and the strand defined by those transcripts. We used somatic mutations from whole genome sequencing for 505 tumor samples from 14 tumor types published previously (Table S1 ) (Fredriksson et al. 2014 discarding those with a precise allelic match to a germline variant in dbSNP138. We searched for significantly mutated regions (SMRs) using a sliding-window approach, whereby along each gene locus we tested all overlapping windows of fixed length that harbored at least one mutation. As RNA binding proteins (RBPs) interact with pre-mRNAs through short nucleotide stretches, we considered windows of size 7. Using shorter windows increased the number of calculations but the results were similar, whereas with larger windows we lost positional resolution (data not shown). For each 7-mer window, we performed a double statistical test to determine the enrichment and to account for local variations and nucleotide biases in mutation rates. Given a window with n mutations in a gene of length L and N mutations overall, we performed a binomial test using N/L as the expected local mutation rate. All tested windows in a gene were adjusted for multiple testing using the Benjamini-Hochberg (BH) method. We kept only 7-mer windows that passed a false discovery rate (corrected p-value) threshold of 0.05.
Although our p-values are various orders of magnitude lower than the expected values, the discarded cases showed a trend similar to the expected values ( Figure S1 ).
To account for potential nucleotide biases we performed a second test per 7-mer window: we compared the mutation count in a given window with the expected count according to the distribution of mutations at each nucleotide in the same gene locus as follows: For each base a we calculated the rate of mutations falling in that base along a
gene R(a) = m(a)/n(a),
where n(a) is the number of a bases in the gene and m(a) is the number of those bases that are mutated. The expected mutation count is then calculated using the nucleotide counts in the window and the mutation rate per nucleotide. For instance, for the 7-mer window AACTGCAG,
the expected count was calculated as: E = 3R(A) + 2R(C) + 2R(G) + R(T). This was compared to
the actual number of mutations, n, observed in that window to define a nucleotide bias (NB) score: NB-score = log2( n / E ) for each 7-mer window. We discarded 7-mer windows corresponding to single-nucleotide repeats (e.g. AAAAAAA). Further, we compared the NBscores of windows with only 1 mutation with windows with >= 3 mutations and set the NB-score to be > 6 ( Figure S1 ). For 7-mer windows that overlap any of the three intronic or exonic bases around the exon-intron boundaries, we kept all windows with 1 or more mutations as long as the NB-score was greater than 6.
Significant 7-mer windows were classified according to the genic region in the same strand on which they fell: 5' or 3' untranslated regions (5UTR/3UTR), coding sequence (CDS), exon in short or long non-coding RNA (EXON), 5'/3' splice-site (5SS/3SS), or intron (INTRON).
To unambiguously assign each 7-mer window to a region type, we prioritized the assignment as 
Comparison to expression, replication timing and LARVA
Data for replication time was obtained from (Lochovsky et al. 2015) . Only SMRs for which replication time was available were analyzed. Expression data were analyzed for the samples from the PAN505 cohort (see below). For each SMR in the PAN505 cohort, we considered annotated transcripts whose genomic sequence overlapped with an SMR. We then calculated the total expression in transcripts per million (TPM) units for the overlapping transcripts per patient and averaged them across patients. For each SMR we compared the average expression of the SMR-containing transcripts in the mutated samples with the number of mutations. Additionally, we analyzed all SMRs with LARVA (Lochovsky et al. 2015) using the same mutation dataset. Specifically, we compared the significance of our SMRs with the significance given by LARVA using the model with a beta-binomial distribution and the replication timing correction (p-bbd-cor), which accounts for overdispersion of the mutation rates and regional biases.
Control regions for SMR comparison
For each set of SMRs (5SS, 3SS, CDS, 5UTR, 3UTR, INTRON, EXON), we generated control regions by random sampling non-overlapping regions from the Gencode annotation. For each SMR, we generated 100 control regions of the same length and same type, without mutations, and allowed for a maximum variation of G+C content of 5%. Each of these 100 controls were separated into different sets to generate 100 control sets of the count as the SMRs, each with similar distribution and G+C content distributions. For the 5SS and 3SS SMRs we generated controls by sampling regions with the same length and same relative position from the exonintron boundary, with no mutations and also controlling for GC content.
Motif analysis
We performed an unbiased search for enriched k-mers (k=6) on the SMRs using MoSEA (https://github.com/comprna/MoSEA) (Sebestyén et al. 2016 ). For each 6-mer within an SMR, we counted the number of SMRs and control regions in which it appeared. A z-score was computed for each individual 6-mer comparing the observed frequency with the distribution of frequencies in the 100 control regions. The enrichment analysis was repeated, reversing the strand of all SMRs and control regions, and those 6-mers that appeared significantly enriched in the direct and reversed analyses for the same region type were discarded. We considered significantly enriched 6-mers with a z-score > 1.96 and with 5 or more counts on SMRs. This analysis included the GT and AG containing 6-mers at 5SS and 3SS splice sites, respectively.
In total we obtained 444 enriched 6-mers (Table S3 ) in 3456 SMRs (Table S4) . From all 20307
SMRs, 749 (3,68%) appeared in both strands due to overlapping genes. However, considering the 3456 SMRs with enriched 6-mers, only 25 (0,72%) overlapped with opposite strands, which is a significant reduction (Fisher's exact test p-value = 2.2e-16, odds-ratio = 5.25). To label enriched 6-mers we used DeepBind (Alipanahi et al. 2015 ) to score each 6-mer using models for 522 proteins containing KH (24 proteins), RRM (134, 2 in common with KH) and C2H2 (366 proteins) domains from human (413 proteins), mouse (49 proteins) and Drosophila (60 proteins). For each 6-mer, we kept the top three predictions with a score > 0.1. Subsequently, given all 6-mers associated to the same RBP label, we kept only those 6-mers that were at a maximum Levenshtein distance of 2 from the top-scoring 6-mer.
Significant mutations per position of a motif
For each of the RBP labels we located all the associated 6-mers in SMRs and performed a multiple sequence alignment (MSA) with all the 6-mers instances using ClustalW (Thompson et al. 2002) . Sequence logos were built from this alignment and somatic mutations were counted per position relative to the MSA. As a control, we shuffled the same number of mutations along the aligned positions to calculate an average per position. Germline mutations from the 1000 genomes project (1000 Genomes Project Consortium et al. 2010 were also considered to calculate the number of germline mutations per position of the MSA.
Gene set enrichment analysis
Annotations for gene sets and pathways were obtained from the Molecular Signatures Database v4.0 (Liberzon et al. 2015) . We performed a Fisher's exact test per hallmark set for genes harboring SMRs with labeled enriched motifs in the following way: for each RBP motif and each gene set, we built a contingency matrix with the counts of genes with and without an RBP motif in an SMR, and within or outside each gene set.
RNA-seq data analysis
TCGA RNA-seq data was obtained for the PAN505 samples from the Genomic Data Commons (Grossman et al. 2016 ) (https://gdc-portal.nci.nih.gov/). We estimated transcript abundances for the Gencode annotations (v19) in TPM units using Salmon (Version 0.8.1) (Patro et al. 2017 ).
For each mutated position in an enriched motif, we calculated whether the mutation was associated to a change in transcript expression using an outlier statistic. For each SMR with an enriched motif and for each transcript whose genomic extension contained the SMR, we compared the transcript log 2 (TPM+0.01) for each patient with a mutation on the motif, with the distribution of log 2 (TPM+0.01) values for the same transcript in the patients from the same tumor type with no mutations in the motif. We only considered those cases where at least 5 patients lacked a mutation. We kept only those cases with |z-score|>1.96 and with a difference between the observed log 2 (TPM+0.01) and the mean of log 2 (TPM+0.1) in patients without mutations greater than 0.5 in absolute value. We considered as significant those cases with a pvalue < 0.05 after adjusting for multiple testing using the BH approach. RNA-seq reads were also mapped to the human genome (hg19) with STAR (version 2.5.0) (Dobin et al. 2013 ) and analyzed using Junckey (https://github.com/comprna/Junckey). From the BAM files, we identified all possible exon-exon junctions defined by spliced reads that appeared in any of the samples. All defined junctions were then grouped into junction-clusters. Any two junctions were placed in the same cluster if they shared at least one splice-site. Clusters were built using all junctions present in any patient, but junction read-counts were assigned per patient, i.e. 0 or more. Only clusters that had at least a total of 30 reads in all samples were used. Additionally, we only used junctions <100kbp in length and with a total of >1% of reads from the cluster in all samples. Then, for each patient, the read-count per junction was normalized by the total read count in that cluster to define the junction inclusion level or proportion spliced-in (PSI). A junction not expressed in a sample was given a zero inclusion level. The software for junction analysis is available at https://github.com/comprna/Junckey. For each SMR containing an enriched motif, we compared each patient with a mutation in the motif against all patients for the same tumor type who did not have mutations in the same SMR. We measured a z-score derived from the PSI for each junction overlapping the motif, by comparing with the of PSIs for the same junction in the non-mutated patients, and we kept only those cases with |z-score|>1.96 and |ΔPSI|>0.1. We considered significant those changes with p-value < 0.05 after adjusting for multiple testing using the BH approach.
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